F. Ye

发表

Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.

W. Liang, W. Mao, Zhidong Liu, 2021, The Lancet. Respiratory medicine.

Effects of sub-lethal antimicrobial photodynamic therapy mediated by haematoporphyrin monomethyl ether on polymyxin-resistant Escherichia coli clinical isolate.

Youjun Feng, Yanhong Ji, Yanli Wang, 2021, Photodiagnosis and photodynamic therapy.

Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion

S. Ren, Caicun Zhou, Q. Chu, 2021, Annals of translational medicine.

lncRNA ITGB8-AS1 functions as a ceRNA to promote colorectal cancer growth and migration through integrin-mediated focal adhesion signaling

Xiaoting Lin, Jinyun Du, Jia Yi, 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer

W. Jiang, Ming Zhu, Yandong Li, 2023, Journal of Translational Medicine.

Equipping Natural Killer Cells with Cetuximab through Metabolic Glycoengineering and Bioorthogonal Reaction for Targeted Treatment of KRAS Mutant Colorectal Cancer.

Xuefei Huang, Yunpeng Tian, Ting Wu, 2021, ACS chemical biology.

Transcription factor KLF15 inhibits the proliferation and migration of gastric cancer cells via regulating the TFAP2A-AS1/NISCH axis

Xin Zhao, Jingxun Wu, J. You, 2021, Biology direct.

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

H. Pan, Yanqiu Zhao, P. Xing, 2021, Cancer communications.

CircPVT1 promotes ER‐positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS

Hai-hua Huang, Jia Yi, Jian-cheng Ding, 2023, The EMBO journal.

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study

Wei Li, F. Gao, Y. Ba, 2023, BMC Medicine.

EZH2 inhibitor Tazemetostat synergizes with JQ-1 in esophageal cancer by inhibiting c-Myc signaling pathway

N. Ding, A. You, F. Ye, 2023, Medical Oncology.

A Sensitive LC-MS/MS Method for the Determination of Afatinib in Human Plasma and Its Application to a Bioequivalence Study.

Xi Luo, W. Zhu, Jin-Ling Yi, 2021, Journal of chromatographic science.

Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.

S. Fan, D. Ji, Yue Ma, 2024, European journal of cancer.

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study

W. Feng, K. Ma, G. Selvaggi, 2024, Cancer communications.

Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study

Jun Zhao, Q. Miao, Jianguo Sun, 2023, BMC cancer.

First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study.

Y. Bai, Jufeng Wang, Shegan Gao, 2024, Nature medicine.